Recent trends in treatment demand and treatment provision in Europe

Implementation of TDI /treatment-related data monitoring in Europe

EMCDDA TDI/treatment expert meeting

8–9 June 2016
EMCDDA, Lisbon
Introduction: purpose and objectives

The purpose of the EMCDDA 2016 TDI/treatment expert meeting is to facilitate the exchange among European experts on the latest developments on the monitoring of drug treatment demand and provision. The meeting has the objectives to discuss with national representatives the current achievements and areas for improvement, as well as provide a space for sharing experiences and discuss technical and implementation issues related to the collection and analysis of treatment-related data.

The focus of this year’s two-day meeting will be the results from the second year of implementation of the new TDI protocol (version 3.0) and the EMCDDA treatment monitoring strategy. Around these two topics, more specific discussions will take place on recent trends and new threats observed through treatment-related data, new methodological developments in terms of drug treatment monitoring, as well as further exploration of the treatment population beyond treatment entrants in the EU and in the neighbouring countries. The discussion will also integrate other areas relevant to drug treatment monitoring, such as monitoring dual diagnosis among treatment patients, treatment outcomes and cost as well as understanding the balance between access to opioid substitution treatment and prevention of diversion. The overall purpose of this year’s meeting is to reinforce and improve the information collected through existing monitoring tools in the area drug treatment.

The outcome of the meeting will be a rapid communication which will compile the discussions and analysis presented during this two day meeting. It will be disseminated among our national experts, the wider Reitox network and all stakeholders interested in recent trends in treatment demand and treatment provision in Europe. This document should serve as a reference point for our network of treatment experts.

For more information on the EMCDDA, visit www.emcdda.europa.eu

Wednesday 8 June 2016
TDI/DRID meeting

Plenary Session: joint TDI/DRID session
Conference Centre

09.30 Interpreting and using behavioural variables from TDI and DRID — Chairs: Anastasios Fotiou and Linda Montanari, Rapporteur: Eleni Kalamara

Objective: this is a follow up of previous meeting which aimed to discuss consistencies and inconsistencies between behavioural data collected through DRID and TDI sources, based on examples presented by the national experts and on an EMCDDA overview. The potential utility of these data as well as difficulties for cross-checking and increasing coherence between the different sources will be discussed further.

Introduction: what are the main issues, gaps, and potential for joint analysis of behavioural data in DRID and TDI — Linda Montanari, Isabelle Giraudon, Eleni Kalamara, Bruno Guarita

Country presentations from:
- Latvia (Anda. Kivite)
- Croatia (Marko Markus)
- Germany (Esther Dammer)

Discussion
Conclusions

11.00 Coffee break
### Wednesday 8 June 2016

**TDI/treatment expert meeting**

**Session 1: Plenary**

**Conference Centre**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Content</th>
</tr>
</thead>
</table>
| 11:30 | **TDI 3.0 implementation and 2016 treatment related activities** — Chair: Linda Montanari, Rapporteur: Brendan Hughes  
*Objective:* update on main issues related to TDI/treatment monitoring and discuss follow-up actions  
Welcome and introduction — Roland Simon  
Overview of the agenda, introduction and overview of TDI implementation — Linda Montanari  
Overview of the last TDI/Treatment-related data — Linda Montanari, Bruno Guarita, Alessandro Pirona  
Treatment workbooks: process and outcome from the first round of feedback — Alessandro Pirona  
Update on FONTE Templates: TDI and ST24 — Bruno Guarita  
Update on treatment tools revision (ST24 and SQ27) — Alessandro Pirona  
TDI/Treatment monitoring IPA–ENP beneficiaries — Sandrine Sleiman  
Discussion  
Psychiatric comorbidity in Europe: presentation of the main outcome from the EMCDDA Insights report — Marta Torrens |
| 13.00 | Lunch break |

**Session 2: Parallel workshops**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room 107</th>
<th>Room 106</th>
</tr>
</thead>
</table>
| 14.30 | **Workshop 1: Recent trends and new threats among patients entering drug treatment**  
Chairs: Craig Wright and Linda Montanari, Rapporteur: Claudia Ranneries  
NPS-related treatment demands in Hungary: the picture beyond TDI data — Gergely Horváth Csaba (Hungary)  
New psychoactive substances as reason for entering treatment in Latvia — Diana Vanaga (Latvia)  
Treatment in prison, Ireland 2008 to 2014 — Suzi Lyons (Ireland)  
Methamphetamine and oxycodone use among drug treatment clients in Cyprus — Ioanna Yasemi |
|       | **Workshop 2: Balancing access to opioid substitution treatment, quality and prevention of diversion: a comparative analysis**  
Chair: Alessandro Pirona, Rapporteur: Dagmar Hedrich  
Brief presentations from project participants: Alexander Grabenhofer-Eggerth (Austria), Christophe Palle (France), Barbara Janikova (Czech Republic), Esther Dammer (Germany), Airi Partanen and Jani Selin via video (Finland), Boguslawe Bukowska (Poland). |
| 16.00 | Coffee break |
### Session 3: Plenary

**Conference Centre**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 16.30 | **The implementation of the EMCDDA treatment monitoring strategy** — Chair: Roland Simon, Rapporteur: Grethe Lauritzen.  
Objective: provide an update on the implementation of the treatment monitoring strategy and discuss further developments  
Treatment monitoring strategy — Dagmar Hedrich  
Determining the total population in treatment and the TDI prevalence with short examples from Finland (Martta Forsell) and Greece (Ioulia Bafi)  
Characterising treatment provision through treatment facility surveys (e.g. EFSQ) — A short example from the Czech Republic (Barbara Janikova) and from Hungary (Gergely Horváth Csaba)  
Conclusions |
| 17.30 | End of day                                                             |

---

### Thursday 9 June 2016

**Session 4: Parallel workshops**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 9.00  | **Objective:** discuss new developments in treatment data collection: total treated population and methodological developments  
Room 107  
**Workshop 3: TDI Prevalence and total treated population**  
Chair: Alessandro Pirona, Rapporteur: Ilze Jekabsone  
United Kingdom — Andrew Jones  
Greece — Anastasios Fotiou  
Austria — Alexander Grabenhofer-Eggerth |
|       | **Room 012**  
**Workshop 4: Methodological and technical developments in TDI data collection: unique identifier and linkage with health databases**  
Chair: Bruno Guarita, Rapporteur: Sandrine Sleiman  
Healthcare trajectories and medication consumption of substance users in treatment: linking TDI and IMA databases (Belgium) — Jérôme Antoine  
The developments in the Estonian TDI system (Estonia) — Maris Salekešin  
The implementation of the Polish TDI monitoring system with unique identifier (Poland) — Anna Strzelecka  
The SIND system in Italy (Italy) — Liliana La Sala and Natalia Magliocchetti |
| 10.30 | Coffee break                                                         |
Recent trends in treatment demand and treatment provision in Europe

**Programme**

**Session 5: Parallel practical oriented workshops**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Workshop</th>
<th>Objective: discuss practical implementation of TDI and treatment data monitoring and practice diagnostic tool on psychiatric comorbidity</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.00</td>
<td>Room 107</td>
<td>Workshop 5: Data quality issues, including key indicators assessment</td>
<td>Chairs: Linda Montanari and Bruno Guarita, Rapporteur: Ilze Jekabsonė Discussion on results and methodology of the key indicator assessment and main data quality issues in TDI</td>
</tr>
<tr>
<td></td>
<td>Room 012</td>
<td>Workshop 6: Mapping treatment systems and implementing facility surveys in IPA beneficiaries</td>
<td>Chairs: Alessandro Pirona and Barbara Janikova, Rapporteur: Sandrine Sleiman Training module on how to map drug treatment facilities and implement facility surveys with the participation of: Irena Ceko (Albania), Višnja Banjac (Bosnia Herzegovina), Lindor Bexheti (Kosovo (1)), Meri Trajkovska (Former Yugoslav Republic of Macedonia), Mira Kovacevic (Serbia).</td>
</tr>
<tr>
<td></td>
<td>Room 106</td>
<td>Workshop 7: Dual Diagnosis Screening Instrument (DDSI)</td>
<td>Chairs: Lubomir Okrulica and Marica Ferri, Rapporteur: Dragica Katalinic Dual Diagnosis Screening Instrument (DDSI): how to do a diagnosis on dual diagnosis (Joan Mestre)</td>
</tr>
<tr>
<td></td>
<td>12.30</td>
<td>Lunch break</td>
<td></td>
</tr>
</tbody>
</table>

**Session 6: Plenary**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Objective: explore recent development on implementation of monitoring outcome, relapse and costs in drug treatment Trends in high-risk cannabis use in treatment demand and multi-indicator analysis Relapse from treatment: the Dutch experience — Wil Kuijpers, Jeroen Wisselink Update on EMCDDA Best practice portal — Marica Ferri Treatment outcomes — Lucas Wiessing The cost of treatment — Claudia Costa Storti</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00</td>
<td>Conference Centre</td>
<td>Treatment outcomes and cost of treatment — Chair: Marica Ferri, Rapporteur: Alessandra Bo</td>
</tr>
</tbody>
</table>

**Session 7: Plenary**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Conclusion:</th>
<th>Chair: Dagmar Hedrich, Rapporteur: Isabelle Giraudon Meeting conclusions presented by Linda Montanari and Alessandro Pirona</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.00</td>
<td>Conference Centre</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>End of the meeting</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(1) This designation is without prejudice to positions on status, and is in line with UNSCR 1244 and the ICJ Opinion on the Kosovo declaration of independence.